ID   MCF-7/LY2
AC   CVCL_9579
SY   LY2; LY-2
DR   CLO; CLO_0009913
DR   EFO; EFO_0001199
DR   ArrayExpress; E-TABM-157
DR   cancercelllines; CVCL_9579
DR   Cosmic; 1136350
DR   DepMap; ACH-002325
DR   GEO; GSM1053705
DR   GEO; GSM1172879
DR   GEO; GSM1172972
DR   LINCS_HMS; 51095
DR   LINCS_LDP; LCL-2076
DR   PharmacoDB; LY2_874_2019
DR   Wikidata; Q54904374
RX   PubMed=4029083;
RX   PubMed=17157791;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25960936;
WW   Info; Synapse; JWGray panel; https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 56.10 hours (JWGray panel).
CC   HLA typing: A*02:01,02:01; B*44:02,18:01; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936).
CC   Selected for resistance to: ChEBI; CHEBI_90187; Lilly 117018 (LY 117018).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 30
//
RX   PubMed=4029083; DOI=10.1210/endo-117-4-1409;
RA   Bronzert, Diane A.
RA   Greene, Geoffrey L.
RA   Lippman, Marc E.
RT   "Selection and characterization of a breast cancer cell line resistant
RT   to the antiestrogen LY 117018.";
RL   Endocrinology 117:1409-1417(1985).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590;
RA   Daemen, Anneleen
RA   Griffith, Obi L.
RA   Heiser, Laura M.
RA   Wang, Nicholas J.
RA   Enache, Oana M.
RA   Sanborn, Zachary J.
RA   Pepin, Francois
RA   Durinck, Steffen
RA   Korkola, James E.
RA   Griffith, Malachi
RA   Hur, Joe S.
RA   Huh, Nam
RA   Chung, Jongsuk
RA   Cope, Leslie
RA   Fackler, Mary Jo
RA   Umbricht, Christopher Benedict
RA   Sukumar, Saraswati
RA   Seth, Pankaj
RA   Sukhatme, Vikas P.
RA   Jakkula, Lakshmi R.
RA   Lu, Yi-Ling
RA   Mills, Gordon B.
RA   Cho, Raymond J.
RA   Collisson, Eric A.
RA   van 't Veer, Laura J.
RA   Spellman, Paul T.
RA   Gray, Joe W.
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel, Sebastian
RA   Lower, Martin
RA   Bukur, Thomas
RA   Sahin, Ugur
RA   Castle, John C.
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521;
RA   Neve, Richard M.
RA   Chin, Koei
RA   Fridlyand, Jane
RA   Yeh, Jennifer
RA   Baehner, Frederick L.
RA   Fevr, Tea
RA   Clark, Laura
RA   Bayani, Nora
RA   Coppe, Jean-Philippe
RA   Tong, Frances
RA   Speed, Terry
RA   Spellman, Paul T.
RA   DeVries, Sandy
RA   Lapuk, Anna
RA   Wang, Nick J.
RA   Kuo, Wen-Lin
RA   Stilwell, Jackie L.
RA   Pinkel, Daniel
RA   Albertson, Donna G.
RA   Waldman, Frederic M.
RA   McCormick, Frank
RA   Dickson, Robert Brent
RA   Johnson, Michael D.
RA   Lippman, Marc E.
RA   Ethier, Stephen P.
RA   Gazdar, Adi F.
RA   Gray, Joe W.
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310;
RA   Timmerman, Luika A.
RA   Holton, Thomas
RA   Yuneva, Mariia
RA   Louie, Raymond J.
RA   Padro, Merce
RA   Daemen, Anneleen
RA   Hu, Min
RA   Chan, Denise A.
RA   Ethier, Stephen P.
RA   van 't Veer, Laura J.
RA   Polyak, Kornelia
RA   McCormick, Frank
RA   Gray, Joe W.
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//